CD55 / Decay Accelerating Factor (DAF) [143-30]



Recognizes a single chain glycoprotein of 70kDa, identified as CD55/DAF. It is widely expressed on cells throughout the body including leukocytes, erythrocytes, epithelium, endothelium, and fibroblasts. It is a Glycosyl phosphatidylinositol anchored (GPI-anchored) member of the membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. It prevents the amplification steps of the complement cascade by interfering with the assembly of the C3-convertases, C4b2a and C3bBb, and the C5-convertase, C4b2a3b and C3bBb3b. CD55 also serves as receptor for CD97 and for echovirus and Coxsackie B virus. The MAb 143-30 may be used as marker for paroxysmal nocturnal hemoglobinuria (PNH).

Product Properties & Targets

Species Reactivity
Cellular Localization
Cell membrane, Secreted
Light Chain
Gene Name
Positive Control
Jurkat cells or human lymphocytes. Human lymph nodes and tonsils.
PHA stimulated human PBL
Alternate Names
Complement decay-accelerating factor, CD55; CD55 Cromer blood group system; Complement decay-accelerating factor; CROM; DAF; GPI-DAF; Decay Accelerating Factor for Complement; Decay accelerating factor GPI-form; Decay accelerating factor soluble-form

Database Links

Entrez Gene ID

Additional Information

Human Gene Symbol
Chromosome Location
Mol. Weight of Antigen


  • This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829).
  • (Microbial infection) Acts as a receptor for Coxsackievirus A21, coxsackieviruses B1, B3 and B5.
  • (Microbial infection) Acts as a receptor for Human enterovirus 70 and D68 (Probable).
  • (Microbial infection) Acts as a receptor for Human echoviruses 6, 7, 11, 12, 20 and 21.

Known Applications & Suggested Dilutions

  • Flow Cytometry (1-2ug/million cells)
  • ,Immunofluorescence (1-2ug/ml),Optimal dilution for a specific application should be determined.

Key References

  • Kishimoto T. et al., eds. Leukocyte Typing VI, Garland Publishing, Inc, New York and London, 1997.Koretz, K. et al., Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. British J. Cancer 66: 810-814, (1992).

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “CD55 / Decay Accelerating Factor (DAF)”

Your email address will not be published. Required fields are marked *

Recombinant mouse monoclonal antibodies and recombinant rabbit monoclonals to support your research

Shop Primary Antibodies